RheumNow Podcast – To Celiac Test or Not? (9.4.20)
Dr Jack Cush reviews the news, journal articles and takes a few Back Talk questions this week:
Treatment Options for Extraintestinal IBD
Extraintestinal manifestations (EIMs) frequently accompany inflammatory bowel disease (IBD), often augmenting morbidity and mortality are associated with disease activity and may increase the need for surgery or treatment escalation. A recent review in GUT details th
Update on Polymyalgia Rheumatica and Giant Cell Arteritis
JAMA has published a clinical update of recent studies on giant cell arteritis (GCA).
Canakinumab Tapering in Still's Disease
You can reduce - but not stop - canakinumab therapy in patients who are in complete clinical remission (CR) in children with systemic juvenile idiopathic arthritis (sJIA).
Filgotinib Decision Delayed by FDA
On August 18th, Gilead and Galapagos received a complete response letter (CRL) from the FDA, which will delay consideration of filgotinib (FIL) for the treatment of moderate-to-severe rheumatoid arthritis (RA).
Rheumatic Diseases, Drugs and COVID-19 Guidelines
Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.
DMARD Use Does Not Increase COVID Hospitalization
An observational study of patients with systemic autoimmune inflammatory rheumatic diseases (AIRD) who also had COVID-19 disease shows that AIRD increased the risk of hospitalization, but that the use of disease-modifying antirheumatic drugs (DMARDs) were not associated with hospitalization.
Long-Term Rituximab in ANCA-Associated Vasculitis
The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).
Fighting Hydroxychloroquine Misinformation
JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it.”.
RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)
Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.
Low Risk of COVID in Biologic Treated Rheum Patients
In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population.
RheumNow Podcast – LTF – Listen to Fauci (7.17.20)
Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow.
Social
Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 4 months ago
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study https://t.co/1fiNgBQUbr looks like lower ab response and drops over 6 mths - boosters important in our patients
Links:
Peter Nash @drpnash ( View Tweet )
3 years 4 months ago
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/IoWISgL3SY https://t.co/JV1Yv5Pg9d https://t.co/b8UoQ4zMUV https://t.co/VwNgVQ5End
Dr. John Cush @RheumNow ( View Tweet )
3 years 4 months ago
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders.
https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 4 months ago
11.5% of Crohns pts have TNFi use contraindications (either MS, CHF, neoplasia, infx risk, TNFi AE, comorbidities, SLE. Alternatively GI survey respondents use ustekinumab (76%), vedolizumab (249%), or tofacitinib (0.5%) https://t.co/6ApUz93iS0 https://t.co/PTmnsTd2Wh
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 4 months ago
Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/QUTIbK3r89 https://t.co/FZcTLREida
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 4 months ago
Rheumatologist Survey:
What do you rely on MOST in diagnosing Still’s disease?
Sxs? Labs? Both? Criteria? Fever?
Vote here:
https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 4 months ago
Ustekinumab (IL-12/23i) phase 2 study was successful in #SLE; but the phase 3 LOTUS study of 512 pts, UST was NOT superior to PBO (SRI-4 44% v 56%) at 1 year. Study was halted for lack of efficacy (but no safety concerns). https://t.co/uMY5uPPabA https://t.co/nG2RO6oEJQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 5 months ago
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/WSOCQ8K38p https://t.co/0u28QHtxoJ
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 6 months ago
